Molecular Tumor Board at the Center for Personalized Medicine Tübingen

Molecular Tumor Board at the Center for Personalized Medicine Tübingen: a Prospective Observational Study

Molecular Tumor Board at the Center for Personalized Medicine

Molecular Tumor Board at the Center for Personalized Medicine The study objectives are

• To ensure a prospective documentation of all patients who are referred to the Molecular Tumor Board in routine clinical care
• To prospectively ensure the documentation of MTB patients with an emphasis to clinical outcome parameters progression-free survival (PFS), overall survival (OS) and further response assessments (e.g. peripheral immunmonitoring, imaging parameters)
• To prospectively assess patient-reported outcome of MTB patients
• To evaluate compliance to MTB suggestions in routine clinical care

Inclusion Criteria:

• Given informed consent ("broad consent" of the University Hospital Tübingen)
• ≥ 18 years of age
• Clinical indication for a referral to Molecular Tumor Board by the treating physician

Exclusion Criteria:

• The MTB assists the referring physician with the interpretation and the use of tumor molecular profiling data for deciding on a therapeutic strategy. Therefore, this board is confined to cancer patients and cannot provide any service for non-cancer patients